Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
(World News Science)

- Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores - - Tapering and discontinuation of corticosteroids without pericarditis recurrence - - Markedly lower annualized incidence of pericarditis episodes while on treatment - - Pivotal Phase 3 trial of rilonacept in recurrent pericarditis (RHAPSODY) enrolling; data expected in 2H 2020 - HAMILTON, Bermuda, Nov. 16, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (`Kiniksa`), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, reported final data from an...